GMDA - Gamida Cell Ltd.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
4.9837
-0.0163 (-0.33%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close5.0000
Open5.0000
Bid4.9700 x 800
Ask5.0000 x 1200
Day's Range4.9500 - 5.0100
52 Week Range2.9300 - 15.4100
Volume12,638
Avg. Volume27,343
Market Cap127.615M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.2030
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.60
Trade prices are not sourced from all markets
  • 3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020
    TipRanks

    3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020

    In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to do before any kind of investment is to educate yourself before you make any hasty decisions. Being extra cautious could be an excellent idea.When it comes to the stock market though, “playing it safe” doesn’t always pay off and putting your money on a seemingly ‘sure bet’ that most big players are investing in, might not get you the results you are actually looking for.When you take a deeper look, you’ll notice that there are actually incredible opportunities in “smaller” and less heard of biotech stocks that can bring you closer to the sweet payday.Using TipRanks’ Stock Screener, we’ve highlighted 3 ultra-promising biotechs that are showing upside of nearly 300% and above.Gamida Cell (GMDA) Gamida Cell is a clinical-stage biopharmaceutical company that is creating and developing cell therapies for different types of cancers. The company has its own proprietary nicotinamide-based (or NAM based) cell expansion technology which is pretty much its “trade secret." NAM-based cell expansion takes the natural state of cancer cells and modifies them so that they are no longer harmful to the body.Gamida is hoping to bank on the success of its frontrunner drug ‘omidubicel’ which is expected to be a life-saving stem cell transplant solution for patients with high-risk blood cancers and bone marrow failure disorders. Omidubicel is currently in Phase 3 of its clinical trials.4-star JMP analyst Jason N. Bulter sees the Phase 3 results for omidubicel in 1H20 “as the primary value driver for the stock” and identifies “potential for success based on positive Phase 2 results.” And that’s good enough reason for Bulter to rate the stock an Outperform along with $16 price target. If the price target is reached within 12 months, that would provide a 12-month return of nearly 261%."Our..price target is derived through an NPV analysis of omidubicel sales, for which we project U.S. sales of ~$580MM by 2027 and assign a 75% probability of approval.” the analyst explained.Overall, we can see from TipRanks that Gamida has a “Strong Buy” consensus rating. In the last three months, the stock has received 22 buy ratings and seven hold ratings. Based on these ratings, the average $175 price target on X stock translates into upside of over 10% from the current share price.Gamida stock has a resounding “yes” on Wall Street. TipRanks analytics show that out of three analysts polled in the past 3 months, all three are bullish. The price target of $17.67 shows a potential upside of about nearly 300% from where the stock is currently trading. (See Gamida stock analysis on TipRanks)Nabriva Therapeutics (NBRV) Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70. (See Nabriva stock analysis on TipRanks)PhaseBio Pharmacuticals (PHAS)Rounding out our list is PhaseBio Pharmacuticals, a clinical-stage biopharmaceutical, developing treatments for orphan diseases with cardiopulmonary indications. PhaseBio's stake in the race is PB2452; medication that the company hopes will undo the negative effects of the antiplatelet drug ticagrelor. The company also has a really good second offering in PB1046; its treatment of PAH (pulmonary arterial hypertension), which creates high blood pressure in the arteries of the lungs.The company recently announced that it completed the Phase 2a clinical trial of PB2452 on healthy elderly patients and that the results have been consistent to its former Phase 1 study with younger, healthy patients. This is good news for PHAS and shows that the company is right on track with its clinical trial advances.William Blair analyst Matt Phipps believes “the completion of the Phase 2a study continues a pattern of excellent execution from company management, and we look forward to the full data presentation at an upcoming medical conference and initiation of pivotal trials in the coming months." The analyst added that “the base case...for PB2452, which assumes a peak penetration for ticagrelor of 40% of the addressable market, results in a risk-adjusted net present value of roughly $16 per share.”With that in mind, it's not surprising why Phipps reiterated an Outperform rating on PHAS stock, while boosting his price target to $7.00 (from $5.00).How does Phipps' bullish forecast echo against the word of the Street? Quite positively, it seems, as TipRanks analytics exhibit PHAS as a Strong Buy. Based on 5 analysts polled in the last 3 months, all 5 rate the stock a "buy." Meanwhile, the 12-month average price target stands at $18.33, marking nearly 340% upside from where the stock is currently trading. (See PhaseBio stock analysis on TipRanks)

  • Business Wire

    Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the entry into a research agreement to collect and analyze health outcomes data in patients with hematologic malignancies who receive an allogeneic hematopoietic stem cell transplant (HSCT, or bone marrow transplant) from various donor sources. The CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide.

  • Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?

    Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders...

  • Gamida Cell Enters Oversold Territory
    Zacks

    Gamida Cell Enters Oversold Territory

    Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire

    Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underwriting discounts and commission and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • GlobeNewswire

    ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

    Tel Aviv, Israel, June 25, 2019 (GLOBE NEWSWIRE) --  Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today that on June 24, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced the launch of a proposed follow-on public offering of approximately $30.0 million of its ordinary shares (approximately 4.04 million shares). In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares (up to 606,000 shares) at the public offering price, less underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • Business Wire

    Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the launch of a proposed follow-on public offering of approximately $30.0 million of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares at the public offering price, less underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • Business Wire

    Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, and Lonza (LONN.SW), an integrated healthcare solutions provider, today announced that the companies have entered into a strategic manufacturing agreement. The agreement provides for the future commercial production after potential FDA approval of omidubicel, Gamida Cell’s investigational advanced cell therapy currently in clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant. This agreement follows a successful multi-year clinical manufacturing relationship and provides Gamida Cell with a path to commercial supply of omidubicel.

  • Business Wire

    Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the appointment of Tracey Lodie, Ph.D., as chief scientific officer. Dr. Lodie will be responsible for setting the scientific strategy, synthetic biology and priorities for Gamida Cell, as well as overseeing translational research for our clinical pipeline. “We are delighted to welcome Tracey to Gamida Cell.

  • Business Wire

    Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that two presentations on omidubicel1 (formerly known as NiCord®), an investigational advanced cell therapy in Phase 3 clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant, took place at the International Society for Cell and Gene Therapy (ISCT) 2019 Annual Meeting being held in Melbourne, Australia. The presentations included a summary of clinical and translational data from the completed Phase 1/2 clinical study of omidubicel in patients with high-risk hematologic malignancies, or blood cancers.

  • Business Wire

    Gamida Cell to Hold Annual Meeting of Stockholders

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that its previously scheduled Annual Meeting of Stockholders will be webcast on Tuesday, June 4, 2019, at 10:00 a.m.

  • Business Wire

    Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that the company will participate in two upcoming healthcare conferences taking place in New York City during May.

  • Associated Press

    Gamida Cell: 1Q Earnings Snapshot

    On a per-share basis, the Jerusalem-based company said it had a loss of 62 cents. Gamida Cell shares have dropped 27% since the beginning of the year. _____ This story was generated by Automated Insights ...

  • Business Wire

    Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

    – Announces USAN selection of omidubicel as nonproprietary name for company’s investigational NAM-expanded hematopoietic stem cells –

  • Business Wire

    Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Tuesday, May 7, 2019, at 8:30 a.m.

  • Business Wire

    Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the Solebury Trout Class of 2018 Biotech IPOs Investor Day on Friday, April 26, 2019, at 2:30 p.m.

  • Business Wire

    Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m.

  • Business Wire

    Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board of directors. If elected, Ms. Tomasello will join the compensation committee, and Mr. Wills will join the company’s audit committee, bringing commercial, operational and financial experience to Gamida Cell’s board of directors as the company advances its clinical development candidates: NiCord®, an investigational advanced cell therapy in Phase 3 clinical development designed to enhance and expand the life-saving benefits of hematopoietic stem cell (bone marrow) transplant, and NAM-NK, an investigational, cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma and multiple myeloma.

  • Gamida Cell Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Gamida Cell Sees Hammer Chart Pattern: Time to Buy?

    Gamida Cell Ltd. (GMDA) has been struggling lately, but the selling pressure may be coming to an end soon.

  • Business Wire

    Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

    – Successfully Completed IPO Raising $53.2 Million in Gross Proceeds –

  • Business Wire

    Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that translational data from the completed Phase 1/2 clinical study of NiCord® were reported in an oral presentation at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Houston, Texas. The data demonstrated that treatment with NiCord, an investigational advanced cell therapy designed to enhance and expand the life-saving benefits of bone marrow transplant for patients with hematologic malignancies, resulted in rapid and robust immune reconstitution. “Reconstitution of a patient’s bone marrow and immune system is a crucial factor in recovery following allogeneic hematopoietic stem cell transplant,” said Jaap-Jan Boelens, M.D., Ph.D., Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center.

  • Business Wire

    Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that new data from its NAM-NK and NiCord® programs was presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research taking place in Houston, Texas. Data reported from the first 14 patients in the ongoing Phase 1 study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) demonstrated that NAM-NK was highly active, with three complete responses observed in patients with NHL and one complete response in a patient with MM.